LATEST NEWS

June 2016


Zumutor Team attended the BIO International Convention, held on June 6th to June 9th at San Francisco.

January 2016


Zumutor team attended the J.P. Morgan Healthcare Conference, January 11- 14th, 2016 at San Francisco, CA, USA.

May 2015


Dr. Sunit Maity was among the featured speakers at the 6th Annual Biosimilars Asia held at Shanghai, China in 2015.

May 2016


Mr. Vivek Halan attended the 7th Annual Biosimilars Asia held on 17th and 18th May at Grand Hyatt Shanghai China.

October 2015


Dr. Sunit Maity served as the workshop leader and took part in a panel discussion at the Biosimilars APAC Summit held at Singapore in October 2015.

January 2014


Theramyt appears in Global Industry analyst Inc.’s strategic report on Biobetter trends.

November 2016


Zumutor was at PEGS Europe, 31st October to 4th November, Lisbon

30th March-1st April 2016


Dr. Subhraprakash Chakrabarty attended BioKorea 2016 (between 30th March-1st April) at Seoul, South Korea

June 2015


Dr. Maloy Ghosh was a featured speaker at 4th Annual Biologics World Korea in 2015.

MEDIA COVERAGE

Economic Times

Biopharma company Theramyt Novobiologics gets VC funding

Fortune India

Theramyt COO among the seven women in Fortune “40 under 40 list”

Yourstory

Biopharma company Theramyt Novobiologics gets VC funding

INDIA TODAY

Theramyt COO writes for India Today

Biotechnika

Theramyt featured in Biotechnika’s Interview of the month

PARTNERSHIP WITH VCs

Zumutor is now headquartered in Woburn, MA with R & D Lab in Bangalore, has raised significant capital to pursue its goal of developing treatment-altering biologics.

Its focus on delivering biobetters, biological drugs of tomorrow, combined with significant opportunities for value creation has attracted the attention of several prominent venture capital houses.

Notable among them are:

Accel Partners

a globally known firm that has supported some of the best names in business, such as Facebook, Flipkart, etc.

IDG Ventures

a VC giant that manages more than US$ 6 billion globally, with an India-focussed US$150 million technology venture capital fund

Aarin Capital Partners

which nurture enterprise from incubation till exit, and has a portfolio of companies in emerging business areas

KITVEN Fund

the government-backed Karnataka Information Technology Venture Capital Fund, focussed on investments in Karnataka, India

Kavitha Iyer Rodrigues, CEO, says,

“With these associations, we look to leverage global expertise, M&A experience and support for operational excellence, which will position Zumutor as a key global biotech healthcare player.
Our world-class team of antibody engineers works in convergence with eminent authorities in the field of immune-oncotherapeutics to enable a robust pipeline of new biological entities.”